RE:RE:RE:RE:New Press Release - Theratechnologies Announces Operational Updatescarlet1967 wrote: No they can't and Paul should voluntarily agree to a pay cut. Since they said after part3 completion any potential future clinical research will be funded by partners I suspect some of those 25 employees are preclinical/clinical managers working on the oncology platform. If correct not having in house expertise in my opinion doesn't put them in a good position negotiating with partners.
juniper88 wrote: palinc2000 wrote: Why now?and not before?
Does anyone else find it ironic that the first year's savings will be $2 million USD, which I believe is the same as Paul's salary during that time?
I am sure Paul is a very compentent CEO and all, but can this tiny company reall afford him?
I walked away from this press release wondering what exactly they were saying. I think someone finally convinced them informing investors via press releases is a good thing. I guess someone needs to now convince them to really think about how the press releases could be interpretted and be more clear. I want to read this as they only let R&D folks that were working on F8 formulation go and while they were likley cross-utilized, they have enough folks to continue what is in the current pipeline and oncology will not be effected by these changes. But then they blur the line by stating that they'll only use a partnership for ongoing oncology and NASH research.
Does that mean that they already have a partner and feel confident making this decision now?
Does that mean that the TH-1902 trial is going to stall after this stage of the trial if there is no partner?
Does that mean that the endpoint that wasn't met recently isn't going to get a different result and the new injection method is now irrelevant?
Does that mean that these folks could have been cut sooner or were they strategically needed for some purpose that now no longer remains?
I still applaud them for releasing frequent updates, even if it creates more questions in the short-term. They'll have a chance to directly address those specific questions and we still have more insight than before. I'm glad they are repositioning the company to be cash flow positive and have the ability to repay debt. Oncology will be no good to us if we are bankrupt. And right now, the market HATES THTX.